Skip to main content

ADVERTISEMENT

quality of life

Research in Review
08/10/2017
JCP Editors
Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia (AML), according to a recent study published in the Journal of Clinical Oncology (online August 7, 2017;...
Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia (AML), according to a recent study published in the Journal of Clinical Oncology (online August 7, 2017;...
Use of...
08/10/2017
Journal of Clinical Pathways
Research in Review
08/03/2017
JCP Editors
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The...
08/03/2017
Journal of Clinical Pathways
Research in Review
08/03/2017
JCP Editors
Patients with advanced cancer who visit the emergency department (ED) with delirium have increased rates of hospitalizations and ICU admissions, along with decreased survival rates, according to a recent study...
Patients with advanced cancer who visit the emergency department (ED) with delirium have increased rates of hospitalizations and ICU admissions, along with decreased survival rates, according to a recent study...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
08/02/2017
JCP Editors
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A...
08/02/2017
Journal of Clinical Pathways
Research in Review
08/02/2017
JCP Editors
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...
A...
08/02/2017
Journal of Clinical Pathways
Research in Review
07/26/2017
JCP Editors
Novel agents are predicted to significantly improve lifetime overall survival (OS) and quality-adjusted life-years (QALYs) compared with traditional therapies for patients with chronic lymphocytic leukemia (CLL),...
Novel agents are predicted to significantly improve lifetime overall survival (OS) and quality-adjusted life-years (QALYs) compared with traditional therapies for patients with chronic lymphocytic leukemia (CLL),...
Novel...
07/26/2017
Journal of Clinical Pathways
Research in Review
07/21/2017
JCP Editors
Terminally ill patients’ understanding of their prognosis within the last six months of their life often times remain unchanged, according to a recent study. ----- Related Content Oncology care models improve...
Terminally ill patients’ understanding of their prognosis within the last six months of their life often times remain unchanged, according to a recent study. ----- Related Content Oncology care models improve...
...
07/21/2017
Journal of Clinical Pathways
Research in Review
07/19/2017
JCP Editors
Recent research suggests that 73% of patients with cancer do not discuss the cost of care with their care team, published by the Cancer Support Community (July 18, 2017). ----- Related Content Improving Patient...
Recent research suggests that 73% of patients with cancer do not discuss the cost of care with their care team, published by the Cancer Support Community (July 18, 2017). ----- Related Content Improving Patient...
Recent...
07/19/2017
Journal of Clinical Pathways
Research in Review
07/03/2017
JCP Editors
A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years (QALYs) at a significantly high cost, according to an analysis published in Cancer...
A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years (QALYs) at a significantly high cost, according to an analysis published in Cancer...
A...
07/03/2017
Journal of Clinical Pathways
Research in Review
07/03/2017
JCP Editors
Analysis of high-risk lung cancer screening shows that screening is cost-effective and may offer cost savings if noncurative treatment costs continue to rise, according to new research published in the Journal of...
Analysis of high-risk lung cancer screening shows that screening is cost-effective and may offer cost savings if noncurative treatment costs continue to rise, according to new research published in the Journal of...
...
07/03/2017
Journal of Clinical Pathways